Pulmonary Arterial Hypertension News and Research

RSS

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.

New tools can potentially play key role in early diagnosis of systemic sclerosis

The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference highlight the use of two new tools, which can potentially play a pivotal role in the early diagnosis of Systemic Sclerosis.

14 Jun 2017

New analysis shows high mortality and financial burden for pulmonary disease due to non-tuberculosis mycobacterium (NTM)

The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.

2 May 2017

Cedars-Sinai receives $7.3 million grant to test safety of novel cell-based therapy in treating PAH

Researchers from the Cedars-Sinai Heart Institute and the Cedars-Sinai Department of Medicine are expanding their ongoing evaluation of a novel cell-based therapeutic candidate into the area of pulmonary arterial hypertension (PAH).

6 Dec 2016

No added benefit proven for pulmonary arterial hypertension drug, IQWiG finds

Selexipag is approved for long-term treatment of pulmonary arterial hypertension (PAH) in adults with moderate to severe symptoms.

7 Oct 2016

New report reveals prescription medication costs may increase up to 13% in 2016

Prescription medication costs are expected to rise at least 11 percent, and possibly up to 13 percent, in 2016, according to a new report on national trends and projections in prescription drug expenditures.

18 Jul 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

Circulating angiogenic factor shows PAH biomarker potential

Hepatoma-derived growth factor predicts disease severity and survival in patients with pulmonary arterial hypertension, showing some possible clinical advantages over N-terminal pro-brain natriuretic peptide, researchers report.

5 Jul 2016

New blood test could help predict severity of pulmonary arterial hypertension

Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor (HDGF) are linked to the increasing severity of pulmonary arterial hypertension, a form of damaging high blood pressure in the lungs.

20 Jun 2016

Potential non-invasive screening biomarker for SSc-PAH

Serum asymmetric dimethylarginine may be an effective non-invasive screening biomarker for systemic sclerosis-related pulmonary arterial hypertension, study findings indicate.

16 Jun 2016

Right ventricular echocardiography predicts targeted therapy outcome in PAH

Echocardiography re-assessment of right ventricular function after targeted therapy is sufficient to predict subsequent prognosis in patients with pulmonary arterial hypertension, say researchers.

15 Jun 2016

Reduced RV functional reserve may explain poor SSc-PAH outcomes

Patients who develop pulmonary arterial hypertension as a consequence of systemic sclerosis have poorer right ventricular functional reserve than those with idiopathic disease, research published in Circulation shows.

9 Jun 2016

Elevated endothelial progenitor cells may characterise PAH patients

Plasma levels of endothelial progenitor cells are elevated in patients with pulmonary arterial hypertension, say researchers.

7 May 2016

Pulmonary hypertension impacts walking ability in SSc patients

The results of a meta-analysis show the adverse impact pulmonary hypertension has on the walking stamina of patients with systemic sclerosis.

6 May 2016

More evidence for combination therapy benefits in PAH

Another meta-analysis adds to evidence of increased benefits for patients with pulmonary arterial hypertension who are given combination therapy.

6 May 2016

Detailed digital models of human organs could bring substantial benefits to clinical trials

Computer simulations of disease processes and detailed digital models of our organs could provide more accurate monitoring and outcome measurements for clinical trials, according to research being presented in Sheffield today.

5 May 2016

Novel gene therapy can treat pulmonary hypertension linked with heart failure

Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure, according to a study led by Roger J. Hajjar, MD, Professor of Medicine and Director of the Cardiovascular Research Center at the Icahn School of Medicine at Mount Sinai.

30 Apr 2016